Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults

Influenza Clinical Trial

Official title:

Phase 1 Inpatient Study of the Safety and Immunogenicity of One Dose of Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/Chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H7N3 Infection in the Event of a Pandemic

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00853255
• Other study ID #: CIR 260
• Secondary ID: CIR 260
• Status: Completed
• Phase: Phase 1
• First received: February 26, 2009
• Last updated: December 31, 2012
• Start date: July 2010
• Est. completion date: December 2011

Study information

• Verified date: December 2012
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Over the past decade, avian influenza (AI) has become a major health concern. The development of safe and effective vaccines against avian strains that infect people is important. The purpose of this study is to determine the safety of and immune response of an investigational AI vaccine in healthy adults against the H7N3 strain of avian influenza.

Description:

The current pandemic risk associated with avian influenza H7N3 infection is significant, as an increasing number of humans are infected. H7 influenza transmission usually occurs in humans when they are exposed through direct contact to infected poultry or surfaces and objects contaminated by infected poultry feces. A pandemic occurs when a new influenza subtype emerges that infects humans, causes serious illness, and spreads easily between humans. The development of a safe and effective vaccine is necessary. The purpose of this study is to evaluate the safety and immunogenicity of a one-dose administration of the live, attenuated AI virus vaccine, H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca).

This study will last approximately 180 days. Participation in this study includes one 12-day hospital stay in an isolation unit at the University of Rochester Vaccine Evaluation Isolation Unit at St. Mary's Hospital in Rochester, NY. All participants will receive one dose of vaccine in nasal spray form at study entry. Participants will be admitted to the isolation unit 2 days prior to vaccination. A targeted physical exam, vital signs measurement, and nasal wash will occur daily following each vaccination until discharge. Participants will be discharged after two consecutive nasal washes on or after Day 7 are negative. Blood and urine collection will occur at selected timepoints throughout the study. Follow-up outpatient visits will occur approximately at Days 28, 56, and 180. A nasal wash and adverse events evaluation will occur at each follow-up visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 2011
• Est. primary completion date: August 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• Good general health

• Available for the duration of the trial

• For females, willing to use acceptable forms of contraception for the duration of the study. More information on this criterion can be found in the protocol.

Exclusion Criteria:

• Clinically significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney disease

• Behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may affect study participation

• Previously enrolled in an H7N3 influenza vaccine trial or in any study of an avian influenza vaccine

• Seropositive to the H7N3 influenza A virus (serum hemagglutination inhibition [HI] titer greater than 1:8)

• Illegal drug use or dependency determined by urine test

• Medical, work, or family problems as a result of alcohol or illicit drug use within 12 months prior to study entry

• History of severe allergic reaction

• Allergy to oseltamivir

• Asthma or reactive airways disease within 2 years prior to study entry

• History of Guillain-Barre syndrome

• HIV-infected

• Hepatitis C virus infected

• Positive for hepatitis B surface antigen (HBsAg)

• Known immunodeficiency syndrome

• Use of corticosteroids or immunosuppressive drugs within 30 days prior to vaccination. Participants who have used topical corticosteroids are not excluded.

• Receipt of live vaccines within 4 weeks prior to study vaccination

• Receipt of killed vaccines within 2 weeks prior to study vaccination

• Absence of spleen

• Receipt of blood products within 6 months prior to study vaccination

• Current smoker unwilling to stop smoking for the duration of the study

• Have traveled to the Southern Hemisphere within 14 days prior to study vaccination

• Have traveled on a cruise ship within 14 days prior to study vaccination

• Work in the poultry industry within 14 days prior to or after study vaccination

• Other investigational vaccine or drug within 30 days prior to study vaccination

• Allergy to eggs or egg products

• Other condition that, in the opinion of the investigator, may interfere with the study

• Pregnant or breastfeeding

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Virus Diseases

Intervention

Biological:
• Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Vaccine administered by nasal spray

Locations

Country	Name	City	State
United States	University of Rochester Vaccine Evaluation Isolation Unit, St. Mary's Hospital	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Alexander DJ. Avian influenza viruses and human health. Dev Biol (Basel). 2006;124:77-84. Review. — View Citation

Joseph T, McAuliffe J, Lu B, Jin H, Kemble G, Subbarao K. Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J Virol. 2007 Oct;81(19):10558-66. Epub 2007 Jul 18. — View Citation

Joseph T, McAuliffe J, Lu B, Vogel L, Swayne D, Jin H, Kemble G, Subbarao K. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology. 2008 Aug 15;378(1):123-32. doi: 10.1016/j.virol.2008.05.021. Epub 2008 Jun 27. — View Citation

Skowronski DM, Li Y, Tweed SA, Tam TW, Petric M, David ST, Marra F, Bastien N, Lee SW, Krajden M, Brunham RC. Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada. CMAJ. 2007 Jan 2;176(1):47-53. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of vaccine-related reactogenicity events		During inpatient stage	Yes
Primary	Area under the curve of nasal viral shedding		Days 2 through 9	No
Primary	Development of serum antibody assessed by either HAI or MN assays		Throughout study	No
Secondary	Number of participants infected with the recombinant vaccine candidate		Throughout study	No
Secondary	T-cell mediated and innate immune responses against recombinant vaccine candidate		Throughout study	No
Secondary	Development of serum bank for testing effectiveness of vaccine against future viruses		Throughout study	No